Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Firms Invited To Discuss Advance COVID-19 Vaccine Contracts

Commission Says Strategy ‘Will Avoid Competition Between Us’

Executive Summary

A common EU approach to the purchasing of COVID-19 vaccines has been welcomed by national health ministers. The strategy involves advance payments to companies to help build up manufacturing capacity and reserve quantities of vaccines once they become available.

You may also be interested in...



EU Makes A United Bid For COVID-19 Vaccines

A new EU-wide strategy on procuring potential COVID-19 vaccines through advance purchase agreements has been launched, replacing earlier fragmented efforts by some member states. 

EU To Seek Joint Advance Contracts On COVID-19 Vaccines

Countries naturally want their citizens to have access to any COVID-19 vaccines once they are developed and approved. The European Commission has asked the EU member states for a mandate to negotiate advance contracts on their behalf with pharmaceutical firms, but some are worried the initiative lacks transparency and could lead to unhealthy competition for access at the global level. 

Denmark Planning To Impose Drug Stockpiling Obligations From July

A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142366

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel